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Abstract: In the last decade, genome-wide gene expression data has been collected from a large number of cancer specimens. In many 
studies utilizing either microarray-based or knowledge-based gene expression profiling, both the validation of candidate genes and 
the identification and inclusion of biomarkers in prognosis-modeling has employed real-time quantitative PCR on reverse transcribed 
mRNA (qRT-PCR) because of its inherent sensitivity and quantitative nature. In qRT-PCR data analysis, an internal reference gene is 
used to normalize the variation in input sample quantity. The relative quantification method used in current real-time qRT-PCR analysis 
fails to ensure data comparability pivotal in identification of prognostic biomarkers. By employing an absolute qRT-PCR system that 
uses a single standard for marker and reference genes (SSMR) to achieve absolute quantification, we showed that the normalized gene 
expression data is comparable and independent of variations in the quantities of sample as well as the standard used for generating stan-
dard curves. We compared two sets of normalized gene expression data with same histological diagnosis of brain tumor from two labs 
using relative and absolute real-time qRT-PCR. Base-10 logarithms of the gene expression ratio relative to ACTB were evaluated for 
  statistical equivalence between tumors processed by two different labs. The results showed an approximate comparability for   normalized 
gene expression quantified using a SSMR-based qRT-PCR. Incomparable results were seen for the gene expression data using relative 
real-time qRT-PCR, due to inequality in molar concentration of two standards for marker and reference genes. Overall results show that 
SSMR-based real-time qRT-PCR ensures comparability of gene expression data much needed in establishment of prognostic/predictive 
models for cancer patients—a process that requires large sample sizes by combining independent sets of data.
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Introduction
In  the  past  decade,  the  traditional  approach  to 
cancer therapy has shifted more towards personal-
ized    medicine.  Molecular  variables  such  as  gene 
expression levels are increasingly used in combina-
tion with clinical variables to model prognosis and 
explain variation in survival and response to thera-
peutic  intervention.1,2  Genome-wide  gene  expres-
sion profiling studies on breast,3 lung,4 prostate,5 and 
recently brain6 cancers have revealed panels of candi-
date gene expression variables. Application of these 
gene expression signatures in cancer should enable 
better  quantification  of  the  residual  risk  faced  by 
patients and indicate the potential value of additional 
treatment. This requires establishment of prognostic 
and  predictive  models  with  statistically  significant 
  discriminative capability.
Although  reports  from  the  MicroArray  Qual-
ity  Control  (MAQC)  project  showed  inter-  and 
intra-platform  reproducibility  of  gene-expression 
measurements,7 concerns remain on direct applicabil-
ity of microarray data to identify molecular markers 
in prognostic modeling of patient survival outcomes. 
Controversial results have been reported on the com-
parability of data derived from different platforms, 
in  addition  to  data  reproducibility8,9  and  statistical 
complexity on model reproducibility.10 Modeling of 
prognosis or patient’s response to treatment requires 
significant sample sizes with an average of ten events 
per  variable  in  a  multivariate  model  to  achieve  a 
meaningful  analysis.10  An  approach  that  evaluates 
only a select number of gene expression variables 
with  a  standardized  gene  expression  quantification 
technology  may  provide  an  efficacious  alternative 
to wide-scale microarray assessment, assuring data 
comparability and satisfying the statistical require-
ments needed to produce a meaningful analysis.2
Real-time quantitative reverse transcription (qRT)-
PCR was developed over the last decade to sensitively 
and  reliably  quantify  mRNA  levels  in  knowledge-
based gene expression studies,11 and has been widely 
used to validate microarray data.12 To normalize the 
variation in sample input, which is a dependent vari-
able of RNA quantification and reverse transcription, 
it is in common practice to use expression of a refer-
ence gene to normalize the marker gene’s expression. 
Both quantities rely either on PCR   efficiency-based 
methods13,14  or  a  standard  curve  based  on    serially 
diluted  cDNA  of  individual  genes  with  known 
quantity,1,15 thus providing a relative quantification. 
As pointed out in our previous study of modeling 
prognosis  for  gliomas,2  absolute  quantification  of 
gene expression can be achieved by “using a multi-
gene (containing) DNA standard for real-time PCR, 
made by ligating the marker gene standard DNA and 
the standards for internal control genes together in 
one piece, in a one-to-one ratio”. In this study, we 
evaluated the comparability of gene expression data 
from two sets of glioma samples of the same histol-
ogy using both a relative and an absolute quantifica-
tion approach. Our data demonstrates that comparable 
gene expression data can be achieved by a standard-
curve based real-time qRT-PCR using the single stan-
dard for marker and reference genes (SSMR).
Method
Single standard for marker 
and reference (SSMR) genes
PCR amplicons of multiple prognostic marker genes 
for gliomas (PAX6, PTEN) and reference genes (ACTB, 
RPS9) were ligated together through multiple cloning 
processes. The multigene-containing DNA fragment 
was then amplified by PCR, purified from gel extrac-
tion, and the molar concentration of standard was cal-
culated based on DNA concentration and molecular 
weight. This SSMR was subjected to a 10-fold serial 
dilution  (1E+10  to  1E+2  molecules  per  4  µl)  with 
10  mM  Tris-HCl,  pH  7.5.  Four  standard  dilutions 
from 1E+6 to 1E+1 depending on the abundance of 
the gene were used for quantifying both marker and 
reference gene expression in cDNA samples.
PCR primers and real-time PCR
Using PrimerDesigner software (Ziren Research LLC, 
Irvine,  CA),  PCR  primers  were  designed  to  avoid 
the amplification of genomic DNA and processing 
pseudogenes of ACTB and PTEN with .90% identity 
in sequence to the corresponding cDNA sequence of 
the gene. Real-time qRT-PCR was carried out using 
either a LightCycler 1.5 instrument in glass capillar-
ies (Roche, Indianapolis, IN) or a StepOne instrument 
in thin-wall PCR plates (Applied Biosystems, Foster 
City,  CA).  Each  reaction  contained  4  µl  standard/
cDNA template, 1 µl 10X primer-MgCl2 mix for the Standardization of gene expression quantification
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gene [final 0.5 µM primer, and 2.5–4 mM MgCl2], 
4  µl  water,  and  1  µl  FAST-START  DNA  Master 
SYBR Green I mix (Roche) following the standard 
PCR program suggested by the manufacturer.
RNA and cdNA samples
Two sets of cDNA samples of glioblastoma multiforme 
(GBM) from our prior modeling of glioma prognosis 
study2 were used. Set I GBM cDNA collected from 
M.D. Anderson Cancer Center (MDACC) were syn-
thesized from total RNA with DNase I treatment and 
used in studies by Sano et al 199916 and Zhou et al 
20031 and described therein. Set II GBM specimens 
were  collected  at  University  of Arkansas  for  Medi-
cal Sciences (UAMS) under an IRB approved proto-
col. Total RNA was extracted using Trizol-based RNA 
isolation approach without DNase I treatment, reverse 
transcribed (∼1 µg of RNA) using reverse transcriptase 
SuperScript  RTII  (Invitrogen)  following  manufactur-
er’s protocol. Both sets of GBM cDNA samples were 
diluted with 10 mM Tris.HCl (pH 7.5) before using in 
real-time PCR.
SSMR-based qRT-PCR quantification 
of gene expressions in glioblastoma 
multiforme (gBM)
We  used  Ziren®  Human  Real-Time  AqRT-PCR 
Standard-1001  (Ziren  Research  LLC,  Irvine)  to 
quantify ABCG2, BMI1, MELK, MSI1, PROM1, and 
ACTB  and  AqRT-PCR  Standard-1020  to  quantify 
PAX6, PTEN, VEGFA, and ACTB for a set of GBM 
cDNA from 87 patients, 66 from MDACC, and 21 
from UAMS. Quantification of CDK4, EGFR, and 
MMP2 was carried out in UAMS and University of 
California, Irvine on two sets of cDNA samples based 
on the same single standard containing these three 
genes, but not the reference gene ACTB. For these 
three genes, the data were a relative ratio to ACTB. In 
order to combine the two sets of relative quantitative 
data in to a single prognosis model, the data in the 
2nd set was adjusted by the mean of fold difference 
between the 2nd vs. the 1st quantification on a set of 
the same cDNA samples from the 1st set.
Statistical analysis
Expression ratios for marker gene relative to refer-
ence gene (ACTB) were converted to their common 
logarithms (“logRatios”), and summarized by lab as 
their mean (SD) and median (quartiles). To evaluate 
samples from different labs for comparability, mean 
logRatios were evaluated for statistical equivalence 
between labs using a confidence-interval version of 
the Two One-Sided Tests (TOST) procedure of Schu-
irmann.17 Briefly, two groups are considered “equiv-
alent to within ±δ” if two one-sided statistical tests 
show that the difference in the two groups’ means 
or  medians  simultaneously  are  (1)  significantly 
more than the lower limit of equivalence at −δ and 
(2) significantly less than the upper limit of equiva-
lence at +δ. When both of the one-sided tests have 
a 5% significance level, then the entire TOST pro-
cedure has a significance level of 5% (not 10%).18 
In terms of confidence intervals, this means that the 
groups are considered equivalent at a 5% signifi-
cance level if their difference has a 90% (not 95%) 
confidence interval that lies entirely inside the upper 
and lower equivalence limits. For these evaluations, 
we considered ±δ = ±0.5 to be reasonable limits of 
equivalence. When there was no detectable expres-
sion of a marker gene in a sample, we left-censored 
the observation at 0.8 times the minimum non-zero 
value  of  that  marker  gene.  To  accommodate  the 
left-censoring, we estimated 90% confidence inter-
vals via the rank-based method of Hodges and Leh-
mann.19 When a gene was not equivalent between 
groups to within ±0.5, the difference between groups 
was further investigated using a single 2-sided Wil-
coxon rank-sum (WRS) test. Statistical analysis was 
conducted using SAS 9.2 software (SAS Institute 
Inc., Cary, NC).
Results
SSMR-based real-time qRT-PCR provides data 
independent of variation in concentration  
of cdNA sample and the standard setting
To  test  the idea of  absolute quantification through 
using SSMR, we first examined how much the quan-
tification  of  gene  expression  varies  in  response  to 
variation of the given quantity of the standard. We 
quantified expression levels of two genes (PAX6 and 
RPS9)  in  the  cDNA  sample  of  a  glioma cell line, 
based on two dilutions of the same SSMR, one of 
truthfully (T) diluted based on calculated DNA molar 
  concentration, while the other falsely diluted (F) with 
half in denoted quantity. Both SSMR dilutions were Zhou et al
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included in the same run with the same defined quan-
tity in standard setting, and generated two standard 
curves to give rise to two gene expression values in the 
tested cDNA samples. As shown in Figure 1A and B, 
a 2-fold difference in gene expression levels for both 
marker and reference genes was seen due to a 2-fold 
difference in the amount of standard, like the result 
of taking a half-foot ruler as one foot to measure the 
same person’s height. This result illustrated that the 
standard curve-based quantification of gene expres-
sion by real-time PCR relies robustly on the quantity 
of standard.
We then compared the ratios of PAX6 to RPS9, with 
each mRNA copy number derived based on the same 
or different standard dilutes. The former is a SSMR-
based  quantification  approach,  while  the  latter  is 
equivalent to using a separate standard for each gene. 
As shown in Figure 1C, the difference in the ratio 
of PAX6/RPS9 in sample cDNA is less than 1.1 fold 
when each mRNA copy number was derived based 
on the SSMR. This was seen even when one standard 
was half the amount of the other in two quantifica-
tions, the input cDNA quantities varied by 10-folds, 
and the quantifications were performed at a different 
time. In contrast, there is a 7-fold difference in the 
ratio of PAX6/RPS9 when each mRNA copy number 
was derived based on the T and F standard dilutions. 
Thus SSMR-based real-time qRT-PCR results in an 
absolute ratio of two genes that is independent of 
variation in concentration of cDNA sample and the 
standard setting.
equivalence and difference in glioma prognosis 
marker gene expression data between labs
We analyzed data comparability for gene expressions 
quantified  using  real-time  qRT-PCR  with  or  with-
out using SSMR in two sets of GBMs of compara-
ble sample size; Set I (n = 38) from MDACC from 
patients operated between 1987–1997; Set II (n = 28) 
with 15 GBMs from MDACC and 13 GBMs from 
UAMS from patients operated between 2003–2006 
(Fig. 2). PAX6 and ACTB mRNA copy numbers were 
derived based on the standard curve of the SSMR for 
PAX6. For normalized PAX6, the estimated difference 
(90% confidence interval) in logRatios was +0.166 
(−0.056 – +0.320) between Set I and set II, thus dem-
onstrating that the two sets are statistically equivalent 
to within ±0.5 with respect to PAX6.
The PTEN mRNA copy number in the same two 
sets of GBMs were derived based on the standard 
curve of a standard for PTEN as reported in our pre-
vious  study.2  The  normalized  PTEN  expression  to 
ACTB was achieved by using the same ACTB mRNA 
copy number derived from the SSMR for PAX6, thus 
a  relative  ratio  of  PTEN  to  ACTB.  The    estimated 
  difference  (90%  confidence  interval)  in  PTEN 
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Figure 1. SSMR-based qRT-PCR provides an absolute ratio for two genes. Quantification of PAX6 and RPS9 expression in a human glioma cell line 
cdNA diluted 100-fold A) and 1000-fold B) after reverse transcription from 5 µg of total RNA in 10 µl. The derived mRNA copy numbers were based on 
the truthfully (T) diluted and falsely (F) 2-fold further diluted SSMR, as shown by Open and filled boxes, respectively. Bar heights (error bars) represent 
means (Sds) from 3 independent repeats of real-time PCR. c) Comparison of the ratios of PAX6/RPS9 with quantity of each mRNA derived based on the 
same or a different standard dilution.Standardization of gene expression quantification
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  logRatios was +1.484 (+1.208 – +1.720) between Set I   
and Set II, indicating a strong lack of equivalence. 
Because both ends of the confidence interval were 
greater than the upper equivalence limit of +0.500, 
PTEN was further evaluated for a difference between 
labs  via  single  two-sided  WRS  test. As  shown  in 
  Figure  2,  the  difference  in  median  logRatios  was 
1.312 (P , 0.0001), equivalent to a 21-fold differ-
ence between labs in their PTEN/ACTB expression 
ratios, even though the same standards were used for 
Sets I and Set II GBMs but diluted and used by dif-
ferent  users.  Given  the  approximate  comparability 
of PAX6 expression in these two sets of GBMs, the 
dramatic difference in PTEN expression is unlikely 
due to changes in PTEN expression in the two sets 
of  GBMs,  but  attributable  to  changes  in  the  stan-
dard quantity, which is likely due to human error in 
  standard dilution process, as shown in Figure 1.
We then analyzed for equivalence of gene expres-
sions  relative  to  ACTB  that  were  included  in  our 
recent modeling of glioma prognosis that were quan-
tified using SSMR-based real-time qRT-PCR, includ-
ing  the  previously  reported  seven  genes  (CDK4, 
EGFR,  MMP2,  VEGFA,  PAX6,  PTEN,  and  RPS9) 
with  prognosis  values2  and  five  stem  cell  marker 
genes (manuscript under review) that were quantified 
in two sets of GBMs from the two institutes’ patients 
(MDACC  and  UAMS). As  shown  in  Figure  3,  8 
out of 12 genes are statistically equivalent to within 
±0.500 on log10 scale, but 4 (ABCG2, BMI1, MELK, 
and PROM1) out of 12 are not. The largest institu-
tion difference (for ABCG2) is 0.4050 on log10 scale, 
equivalent to a 2.54-fold (2.54x) change in average 
expression ratio of ABCG2 to ACTB between insti-
tutions (P = 0.030 by 2-sided WRS test). The next 
largest  institution  difference  (for  BMI1)  is  0.2961, 
equivalent to a 1.98x change in average BMI1/ACTB 
ratio between institutions (P = 0.038 by 2-sided WRS 
test). The other two non-equivalent genes, MELK and 
PROM1, showed differences ,0.2000 (fold change 
,1.58x)  with  90%  confidence  intervals  that  con-
tained zero, thus showing that these two genes were 
neither statistically equivalent nor significantly dif-
ferent between institutions.
Discussion
Real-time qRT-PCR technique is increasingly being 
used to quantify the expression levels of candidate 
marker genes in the identification of prognostic bio-
markers. This study shows that the relative quantifi-
cation method currently used in real-time qRT-PCR 
technique  does  not  ensure  data  comparability.  We 
introduced the method of using a SSMR in real-time 
qRT-PCR to achieve an absolute ratio of the marker 
and reference gene expression.
Gene expression quantification relies on the stan-
dard quantity for that gene. The standard curve for 
each gene is a linear regression curve between the 
log (10) value of the standard copy number and the 
cross points where the PCR reaches log-amplification. 
Given the accurate measurement of mRNA in the form 
of cDNA, comparing it with other samples requires 
normalization to make the data comparable among 
different samples, which is normally achieved using 
the ratio of the marker gene mRNA quantity to that 
of an appropriate internal reference gene (in practice, 
house-keeping genes). Quantification of the reference 
gene also relies on its own standard in real-time PCR. 
Ideally if the same copy numbers of each marker and 
reference gene standard are used, an absolute ratio 
between them in the sample can be achieved. Thus the 
data will be comparable to that generated   separately 
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Figure 2. Comparison of normalized PAX6 and PTEN expressions in 
two sets of gBMs with or without using SSMR in real-time qRT-PCR. 
Log-transformed ratio of PAX6 to ACTB was an absolute ratio by using 
SSMR, while ratio of PTEN to ACTB was a relative ratio by using two 
separate gene standards. The value of each sample was plotted and the 
median and quartiles for each gene ratio in Set I and II gBMs are shown 
by horizontal and vertical bars, respectively.Zhou et al
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using the same standards for marker and reference 
genes. However, the variation in quantity of the two 
standards and human error in dilution of the standard 
for generating a standard curve may result in data that 
is not comparable, as shown by this study.
In this study, we have used a large number of GBM 
samples from two institutes to perform a valid statis-
tical analysis on comparability of 12 gene expression 
data  obtained  using  SSMR-based  qRT-PCR.  Only 
4 stem cell marker genes are statistically not equiva-
lent between two institute’s GBM samples. Lack of 
statistical equivalence can happen when institutions 
are nearly equal but patient variation is large. It can 
also happen when patient variation is moderate but 
institutions are not so equal, which can be associated 
with changes of diagnosis standard over time. Notice-
ably, the MDACC GBMs were from patients operated 
during 1987–1997, while UAMS from 2003–2006.
The  SSMR-based  real-time  qRT-PCR  method 
allows  independent  data  sets  quantified  at  differ-
ent times or by different labs comparable. We have 
applied it in our recent study of glioma prognosis, 
in which the logratios of marker gene to ACTB were 
used to establish three multivariate prognosis mod-
els:  GBM,  anaplastic  astrocytomas  (AA),  and  oli-
godendroglia tumors with patient’s overall survival 
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time followed to maturation for GBM, 2/3 mature 
for AA  and 1/2 mature for oligodendroglia tumors 
(Manuscript under review). We demonstrated that it is 
pivotal to obtain comparable data, which would allow 
us to combine data from multiple research sites and 
acquire a large sample size required in modeling of 
prognosis and identifying effect of gene expression 
variables. In addition to providing the proper event to 
variable ratio to establish statistically valid models, 
with  standardization  of  gene  expression  quantifica-
tion, the gene variables from prospective patients can 
be directly applied into the model based on retrospec-
tive patients.
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